

# CITATION REPORT

List of articles citing

## Molecular genetics of HBV infection

DOI: 10.3851/imp1619

Antiviral Therapy, 2010, 15 Suppl 3, 3-14.

**Source:** <https://exaly.com/paper-pdf/47627738/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
128	Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs. <b>2011</b> , 92, 382-5		18
127	Epigenetic Regulation of Hepatitis B Virus Infection. <b>2011</b> , 10, 277-284		5
126	Hepatitis B infection: current concepts and future challenges. <b>2012</b> , 105, 109-13		44
125	Pathogenesis of hepatitis B virus infection and potential for new therapies. <b>2012</b> , 73, 581-4		4
124	Progress in DNA vaccination against HBV infection. <b>2012</b> , 7, 149-160		4
123	Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. <b>2012</b> , 12, 307		30
122	Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. <b>2012</b> , 56, 434-43		91
121	Targeted DNA mutagenesis for the cure of chronic viral infections. <b>2012</b> , 86, 8920-36		90
120	Drugs in Development for the Treatment of Chronic Hepatitis B. <b>2012</b> , 11, 111-118		4
119	Long-term monitoring drug resistance by ultra-deep pyrosequencing in a chronic hepatitis B virus (HBV)-infected patient exposed to several unsuccessful therapy schemes. <b>2012</b> , 94, 184-7		11
118	The HepaRG cell line: a valuable in vitro tool for hepatitis virus infection studies. <b>2013</b> , 7, 394-9		1
117	The natural course of chronic hepatitis B virus infection and its management. <b>2013</b> , 67, 247-91		19
116	Hepatitis B vaccines. <b>2013</b> , 205-234		13
115	Detection of HBoV DNA in idiopathic lung fibrosis, Cologne, Germany. <b>2013</b> , 58, 325-7		25
114	GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. <b>2013</b> , 144, 1508-17, 1517.e1-10		281
113	Antiviral Drug Discovery. <b>2013</b> , 439-515		
112	Influence of overlapping genes on the evolution of human hepatitis B virus. <b>2013</b> , 441, 40-8		21

111	An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. <b>2013</b> , 87, 12701-20	29
110	Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. <b>2013</b> , 9, e1003131	34
109	Interleukin-1 and tumor necrosis factor- $\alpha$ trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). <b>2013</b> , 288, 31715-27	111
108	Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment. <b>2013</b> , 57, 343-9	22
107	The incidence of Drug- Resistant Mutants in Patients with Chronic HBV Infection After Lamivudine Treatment. <b>2013</b> , 6,	1
106	Epidemiology of the viral hepatitis B and C in female prisoners of Metropolitan Regional Prison Complex in the State of Goi�s, Central Brazil. <b>2013</b> , 46, 24-9	21
105	Melting curve analysis for the screening of hepatitis B virus genotypes A, D and F in patients from a general hospital in southern Brazil. <b>2013</b> , 50, 219-25	4
104	Emerging antivirals for the treatment of hepatitis B. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 7707-17.6	34
103	Guarding the sleeping giant: hepatitis B screening and management in patients with hematological malignancy. <b>2014</b> , 55, 2426-7	2
102	Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach. <b>2015</b> , 32, 383-403	
101	Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count. <b>2014</b> , 86, 97-101	6
100	Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility. <b>2014</b> , 8, 185-95	14
99	Pre-S mutations of hepatitis B virus affect genome replication and expression of surface antigens. <b>2014</b> , 29, 843-50	7
98	Restitution of gene expression and histone acetylation signatures altered by hepatitis B virus through antiviral microRNA-like molecules in nontransformed murine hepatocytes. <b>2014</b> , 6, 26	8
97	Epidemiology and clinical features of childhood chronic hepatitis B infection diagnosed in England. <b>2014</b> , 33, 130-5	11
96	Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi. <b>2014</b> , 59, 1618-26	26
95	Recent insights into hepatitis B virus-host interactions. <b>2014</b> , 86, 925-32	20
94	Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. <b>2014</b> , 81, 478-84	21

93	Hepatitis B virus PreS/S gene variants: pathobiology and clinical implications. <b>2014</b> , 61, 408-17	165
92	Maladies systémiques et biomédicaments : comprendre, apprécier et prévenir le risque de réactivation d'hépatite B. <b>2014</b> , 81, 374-380	
91	Basis of HBV persistence and new treatment options. <b>2014</b> , 8 Suppl 2, 486-91	4
90	Viruses and human cancers: a long road of discovery of molecular paradigms. <b>2014</b> , 27, 463-81	114
89	Cyclosporin A and its analogs inhibit hepatitis B virus entry into cultured hepatocytes through targeting a membrane transporter, sodium taurocholate cotransporting polypeptide (NTCP). <b>2014</b> , 59, 1726-37	185
88	The differential diagnostic model for serous peptidomics in HBV carriers established by MALDI-TOF-MS analysis. <b>2014</b> , 47, 56-62	10
87	N-glycosylation mutations within hepatitis B virus surface major hydrophilic region contribute mostly to immune escape. <b>2014</b> , 60, 515-22	59
86	Genomic flexibility of human endogenous retrovirus type K. <b>2014</b> , 88, 9673-82	18
85	Hepatitis B virus infection. <b>2014</b> , 384, 2053-63	930
84	The prevalence of mutations in the major hydrophilic region of the surface antigen of hepatitis B virus varies with subgenotype. <b>2015</b> , 143, 3572-82	8
83	Genetic Diversity of the Hepatitis B Virus Strains in Cuba: Absence of West-African Genotypes despite the Transatlantic Slave Trade. <i>PLoS ONE</i> , <b>2015</b> , 10, e0125052	3-7 7
82	Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. <b>2015</b> , 33, 211-9	14
81	Incidence of natural resistance mutations in naïve chronic hepatitis B patients: a systematic review and meta-analysis. <b>2015</b> , 30, 252-61	23
80	Viral hepatitis: past and future of HBV and HDV. <b>2015</b> , 5, a021345	28
79	Hepatic CD206-positive macrophages express amphiregulin to promote the immunosuppressive activity of regulatory T cells in HBV infection. <b>2015</b> , 98, 1071-80	17
78	The infection efficiency and replication ability of circularized HBV DNA optimized the linear HBV DNA in vitro and in vivo. <b>2015</b> , 16, 5141-60	3
77	Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. <b>2015</b> , 13, 979-86	24
76	Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection. <b>2015</b> , 97, 84-103	152

75	Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization. <b>2015</b> , 13, 1325-36		15
74	Antenatal hepatitis B in a large teaching NHS Trust - implications for future care. <b>2015</b> , 70, 72-7		4
73	The hepatitis B virus (HBV) HBx protein activates AKT to simultaneously regulate HBV replication and hepatocyte survival. <b>2015</b> , 89, 999-1012		79
72	Diagnosis of hepatitis B. <b>2016</b> , 4, 338		35
71	Virus and Host Testing to Manage Chronic Hepatitis B. <b>2016</b> , 62 Suppl 4, S298-305		11
70	Activating the innate immune response to counter chronic hepatitis B virus infection. <b>2016</b> , 16, 1517-1527		6
69	Current molecular methods for the detection of hepatitis B virus quasispecies. <b>2016</b> , 26, 369-81		9
68	HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 97-111	1.6	10
67	RNA Exosome Complex Regulates Stability of the Hepatitis B Virus X-mRNA Transcript in a Non-stop-mediated (NSD) RNA Quality Control Mechanism. <b>2016</b> , 291, 15958-74		17
66	Single-Molecule Sequencing Reveals Complex Genome Variation of Hepatitis B Virus during 15 Years of Chronic Infection following Liver Transplantation. <b>2016</b> , 90, 7171-7183		27
65	Pathobiology of Hepatitis B Virus-Induced Carcinogenesis. <b>2016</b> , 95-121		2
64	A novel strategy to reduce very late HIV diagnosis in high-prevalence areas in South-West England: serious incident audit. <b>2017</b> , 39, 170-176		3
63	Wild type HBx and truncated HBx: Pleiotropic regulators driving sequential genetic and epigenetic steps of hepatocarcinogenesis and progression of HBV-associated neoplasms. <b>2016</b> , 26, 57-73		5
62	Prevalence of mutations in HBV DNA polymerase gene associated with nucleos(t)ide resistance in treatment-naive patients with Chronic Hepatitis B in Central China. <b>2016</b> , 20, 173-8		9
61	Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in hepatitis B e antigen-positive chronic hepatitis B patients. <b>2016</b> , 22, 571.e5-9		16
60	Advances in therapeutics for chronic hepatitis B. <b>2016</b> , 10, 277-85		14
59	Virus-host interplay in hepatitis B virus infection and epigenetic treatment strategies. <b>2017</b> , 284, 3550-3572		16
58	Differences in sequences between HBV-relaxed circular DNA and covalently closed circular DNA. <b>2017</b> , 6, e55		5

57	Novel therapies and potential therapeutic targets in the management of chronic hepatitis B. <b>2017</b> , 29, 987-993		4
56	Integrating nested PCR with high-throughput sequencing to characterize mutations of HBV genome in low viral load samples. <b>2017</b> , 96, e7588		4
55	Hepatic expansion of virus-specific CD8BTLA T cells with regulatory properties in chronic hepatitis B virus infection. <b>2017</b> , 311, 36-45		10
54	Present and future DNA vaccines for chronic hepatitis B treatment. <b>2017</b> , 17, 185-195		11
53	Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. <b>2017</b> , 5,		29
52	What is changed in HBV molecular epidemiology in Italy?. <b>2018</b> , 90, 786-795		10
51	CRISPR/Cas9 and Genome Editing for Viral Disease-Is Resistance Futile?. <b>2018</b> , 4, 871-880		9
50	Three types of preS1 start codon deletion variants in the natural course of chronic hepatitis B infection. <b>2018</b> , 33, 1370-1378		4
49	Detection of hyper-conserved regions in hepatitis B virus X gene potentially useful for gene therapy. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 2095-2107	5.6	10
48	De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry. <b>2018</b> , 25, 906-915.e5		35
47	IL-1 $\beta$ /ATF3-mediated induction of Ski2 expression enhances hepatitis B virus x mRNA degradation. <b>2018</b> , 503, 1854-1860		7
46	Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?. <b>2018</b> , 9,		41
45	Hepatitis B Vaccines. <b>2018</b> , 342-374.e17		9
44	Aberrant DNA methylation profile of hepatitis B virus infection. <b>2019</b> , 91, 81-92		3
43	Formation of semi-enveloped particles as a unique feature of a hepatitis B virus PreS1 deletion mutant. <b>2019</b> , 50, 940-954		5
42	Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. <b>2019</b> , 156, 384-399		60
41	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <b>2019</b> , 71, 397-408		163
40	Hepatitis B: Prognosis and Treatment. <b>2019</b> , 490-502		

39	Development of a novel anti-hepatitis B virus agent via Sp1. <b>2020</b> , 10, 47		5
38	Novel Hepatitis B Virus Capsid Assembly Modulator Induces Potent Antiviral Responses and in Humanized Mice. <b>2020</b> , 64,		12
37	Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks. <b>2020</b> , 99, 171-178		7
36	Hepatitis B and C Viruses. <b>2020</b> ,		1
35	The origin and underlying driving forces of the SARS-CoV-2 outbreak. <b>2020</b> , 27, 73		50
34	Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. <b>2020</b> , 21,		15
33	Estimating hepatitis B virus cccDNA persistence in chronic infection. <b>2021</b> , 7, veaa063		8
32	Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B. <i>Viruses</i> , <b>2021</b> , 13,	6.2	5
31	Recent Advances in Hepatitis B Treatment. <b>2021</b> , 14,		6
30	Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis. <i>Viruses</i> , <b>2021</b> , 13,	6.2	1
29	Proteasomal activator 28 gamma stabilizes hepatitis B virus X protein by competitively inhibiting the Siah-1-mediated proteasomal degradation. <b>2021</b> , 578, 97-103		0
28	Research progress of epigallocatechin-3-gallate (EGCG) on anti-pathogenic microbes and immune regulation activities. <i>Food and Function</i> , <b>2021</b> , 12, 9607-9619	6.1	3
27	Hepatitis B virus X protein activates E3 ubiquitin ligase Siah-1 to control virus propagation via a negative feedback loop. <i>Journal of General Virology</i> , <b>2017</b> , 98, 1774-1784	4.9	9
26	Hepatitis B virus X protein activates proteasomal activator 28 gamma expression via upregulation of p53 levels to stimulate virus replication. <i>Journal of General Virology</i> , <b>2018</b> , 99, 655-666	4.9	13
25	HBx natural variants containing Ser-101 instead of Pro-101 evade ubiquitin-dependent proteasomal degradation by activating proteasomal activator 28 gamma expression. <i>Journal of General Virology</i> , <b>2019</b> , 100, 1554-1566	4.9	1
24	Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences. <i>Journal of General Virology</i> , <b>2020</b> , 101, 271-283	4.9	15
23	Estimating hepatitis B virus cccDNA persistence in chronic infection.		2
22	Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences.		1

21	Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand. <i>PLoS ONE</i> , <b>2012</b> , 7, e42184	3.7	8
20	The Influence of Hepatitis B Viral Load and Pre-S Deletion Mutations on Post-Operative Recurrence of Hepatocellular Carcinoma and the Tertiary Preventive Effects by Anti-Viral Therapy. <i>PLoS ONE</i> , <b>2013</b> , 8, e66457	3.7	59
19	Oral administered particulate yeast-derived glucan promotes hepatitis B virus clearance in a hydrodynamic injection mouse model. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123559	3.7	8
18	Novel biomarkers for the management of chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , <b>2020</b> , 26, 261-279	6.9	28
17	Core promoter: a critical region where the hepatitis B virus makes decisions. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 425-35	5.6	51
16	Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 4985-4998	5.6	1
15	Conservation and variability of hepatitis B core at different chronic hepatitis stages. <i>World Journal of Gastroenterology</i> , <b>2020</b> , 26, 2584-2598	5.6	4
14	Hepatitis b virus expression and replication in ovum and the influencing factors. <i>Saudi Journal of Gastroenterology</i> , <b>2016</b> , 22, 215-9	3	4
13	Huh-7 Human Liver Cancer Cells: A Model System to Understand Hepatocellular Carcinoma and Therapy. <i>Journal of Cancer Therapy</i> , <b>2013</b> , 04, 606-631	0.2	13
12	Clinical relevance of hepatitis B virus variants. <i>World Journal of Hepatology</i> , <b>2015</b> , 7, 1086-96	3.4	29
11	[Diagnosis of chronic hepatitis B infection]. <i>Tidsskrift for Den Norske Laegeforening</i> , <b>2013</b> , 133, 1717-21	3.5	
10	NEW METHOD FOR DETERMINING HEPATITIS B VIRUS RESISTANCE MUTATIONS M204I/V TO NUCLEOS(T)IDE ANALOGUES IN PATIENTS WITH CHRONIC HEPATITIS B. <i>Russian Journal of Infection and Immunity</i> , <b>2015</b> , 5, 265-272	0.4	
9	The origin and underlying driving forces of the SARS-CoV-2 outbreak.		1
8	An enzymatic nucleic acid vertical flow assay.. <i>Analytical and Bioanalytical Chemistry</i> , <b>2022</b> , 1	4.4	
7	Lower frequency of T stem cell memory (TSCM) cells in hepatitis B vaccine nonresponders.. <i>Immunologic Research</i> , <b>2022</b> , 1	4.3	
6	Occult Hepatitis B Virus Infection: An Update. <i>Viruses</i> , <b>2022</b> , 14, 1504	6.2	4
5	Synthetic mRNA Gene Therapies and Hepatotropic Non-viral Vectors for the Treatment of Chronic HBV Infections. <b>2022</b> , 157-179		0
4	A Lamivudine/ Entacavir Resistance Mutations Among Treatment Naïve Chronic HBV Infected Patients Mashhad, Iran. <b>2022</b> , 16, 376-382		0



- 3 Tumor Suppressor p53 Inhibits Hepatitis B Virus Replication by Downregulating HBx via E6AP-Mediated Proteasomal Degradation in Human Hepatocellular Carcinoma Cell Lines. **2022**, 14, 2313
- 2 Decreased expression of HBV surface antigen (HBsAg) with sK122R and sV96A co-mutation is associated with an ineffective antibody response in a chronic hepatitis B patient. **2023**, 105431
- 1 Pre-S1 Mutations as Indicated by Serum Pre-S1 Antigen Negative is Associated with an Increased Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients. Volume 10, 599-609